Payer utilization review intensity has measurably increased year over year, not just anecdotally — Medicare Advantage insurers denied 7.7% of prior authorization requests in 2024, up from 6.4% the year before, while overall UR volume keeps climbing across the industry.
- Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, per KFF’s analysis of the latest federal data.
- The denial rate rose from 6.4% in 2023 to 7.7% in 2024 — a real year-over-year increase, not a one-time spike.
- Only 11.5% of denied requests get appealed, even though 80.7% of appeals succeed — the overturn rate has stayed above 80% every year from 2019 through 2024.
- That gap between the overturn rate and the appeal rate is the real cost of rising UR intensity: most facilities that don’t appeal are absorbing denials that would likely have been reversed.
- 2026 brought the first federal response-time mandate for payers, a partial counterweight to rising review intensity, but it doesn’t apply to every plan type.
- Revenue Logic’s own utilization review process treats every denial as an appeal candidate by default, given how consistently the overturn rate has run above 80%.
The Trend Is Real, Not Just a Feeling
Facilities running utilization review day to day often sense that payers are reviewing more aggressively than they used to, and the data backs that impression up. Per KFF’s 2024 analysis, prior authorization denial rates climbed from 6.4% to 7.7% in a single year, on a volume approaching 53 million determinations.
That’s not a fringe statistic from an unusual payer — it’s the aggregate pattern across Medicare Advantage, one of the largest and most closely tracked payer categories in the country. A facility that isn’t seeing its own UR experience toughen year over year is the exception, not the norm. The practical consequence shows up as more continued-stay denials at each concurrent review.
Those three numbers together describe a system where review intensity is rising while the appeal rate stays flat. That combination means the real cost of rising UR intensity isn’t just more denials — it’s more denials that would likely be reversed, sitting unappealed because the appeal rate hasn’t kept pace with the denial rate.
The denial rate measures how often a payer denies a request on first review. The overturn rate measures how often an appealed denial gets reversed. A high overturn rate alongside a low appeal rate signals that many valid requests are being denied and never contested — a gap in process, not in medical necessity.
Why Volume and Denial Rate Are Rising Together
Rising UR intensity isn’t just about stricter clinical criteria — it’s also about payers reviewing more claims in the first place. A 53-million-determination volume at the Medicare Advantage level alone reflects both more claims routed through prior authorization and more scrutiny applied once they get there. Seeing how review intensity varies by payer rather than as an industry average is what turns that trend into something a facility can plan against.
For behavioral health specifically, that trend compounds with the carve-out routing a verification of benefits process should have already flagged. A facility’s claims denial management team is absorbing both a higher volume of reviews and a higher denial rate per review, at the same time.
An appeal success rate that’s held above 80% for six consecutive years isn’t a fluke — it’s a standing signal that the default response to a UR denial should be to appeal, not to accept it as a final answer. The facilities absorbing the most unnecessary loss are the ones treating a denial as the end of the process rather than the start of one.
Where the 2026 Federal Deadline Fits Into the Trend
The rising intensity trend is exactly the backdrop that makes CMS’s new prior authorization response-time rule meaningful. A 72-hour expedited / 7-day standard deadline doesn’t reduce how often payers deny — it just caps how long a facility waits, for the plan types the rule covers.
That’s a real but partial counterweight — rising denial rates plus a faster answer still means more denials overall, just with less uncertainty about timing. Appeal aggressively given the overturn-rate data, and use the response-time floor to plan the financial forecast more precisely where it applies.
Is the rising denial rate specific to Medicare Advantage, or industry-wide?
The clearest year-over-year comparison data comes from Medicare Advantage because of its federal reporting requirements, but the underlying drivers — more claims routed through review, more analytics-driven scrutiny — apply across commercial and Medicaid managed care plans too.
Why would a facility skip appealing a denial that's likely to be overturned?
Appeals take staff time and follow-up discipline that many facilities don’t have built into their process by default. The data suggests that gap, not a lack of merit in the underlying claims, is the main reason so many denials go unappealed.
Does the 2026 federal response-time rule apply to all the plans denying more often?
No — it applies to Medicare Advantage, Medicaid fee-for-service, CHIP, and qualified health plans specifically, not to every commercial employer-sponsored plan contributing to the broader denial-rate trend.
If your facility isn’t appealing every denial by default, contact Revenue Logic and we’ll show you what an 80% overturn rate is actually worth.
- Default-to-appeal denial workflow, built around an 80%+ overturn rate
- UR tracking calibrated to rising payer scrutiny, not last year’s baseline
